Promising drug cocktail takes on deadly brain tumor
NCT ID NCT06419946
First seen Apr 14, 2026 · Last updated May 01, 2026 · Updated 4 times
Summary
This study tests whether adding lomustine to standard temozolomide chemotherapy helps people with a specific type of glioblastoma live longer. It includes 200 adults aged 18-70 with newly diagnosed, MGMT-methylated tumors. Participants are randomly assigned to standard chemo or the combo, starting during radiation. The main goal is overall survival, with side effects and quality of life also tracked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus University Hospital
RECRUITINGAarhus, Denmark
Contact Email: •••••@•••••
-
Gävle Hospital
RECRUITINGGävle, Sweden
Contact Email: •••••@•••••
-
Haukeland University Hospital
RECRUITINGBergen, Norway
Contact Email: •••••@•••••
-
Kalmar Country Hospital
RECRUITINGKalmar, Sweden
Contact Email: •••••@•••••
-
Karolinska Institutet
ENROLLING_BY_INVITATIONStockholm, Sweden
-
Kepler University Hospital
RECRUITINGLinz, Austria
Contact Email: •••••@•••••
-
Medizinische Universität Innsbruck
NOT_YET_RECRUITINGInnsbruck, Austria
Contact Email: •••••@•••••
-
Norrlands Universitetssjukhus, Umea, Sweden
RECRUITINGUmeå, Sweden
Contact Email: •••••@•••••
-
Oslo University Hospital
RECRUITINGOslo, Norway
Contact Email: •••••@•••••
-
Ryhov County Hospital
RECRUITINGJönköping, Sweden
Contact Email: •••••@•••••
Contact
-
Sahlgrenska University Hospital
RECRUITINGGothenburg, Sweden
Contact Email: •••••@•••••
-
Skåne University Hospital
NOT_YET_RECRUITINGLund, Sweden
Contact Email: •••••@•••••
-
Sorlandet Sykehus
RECRUITINGKristiansand, Norway
Contact Email: •••••@•••••
-
St Olavs Hospital
NOT_YET_RECRUITINGTrondheim, Norway
Contact Email: •••••@•••••
-
Stavanger University Hospital
NOT_YET_RECRUITINGStavanger, Norway
Contact Email: •••••@•••••
-
Sundsvall Hospital
ENROLLING_BY_INVITATIONSundsvall, Sweden
-
University Hospital Graz
NOT_YET_RECRUITINGGraz, Austria
Contact Email: •••••@•••••
-
University Hospital St. Pölten
ENROLLING_BY_INVITATIONSankt Pölten, Austria
-
Uppsala University Hospital
RECRUITINGUppsala, Sweden
Contact Email: •••••@•••••
-
Örebro University Hospital
RECRUITINGÖrebro, Sweden
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.